This review discusses the epidemiology of the most clinically relevant opportunistic fungal infections in Latin America, including candidiasis, cryptococcosis, trichosporonosis, aspergillosis, and fusariosis. The epidemiologic features, including incidence, of some of these mycoses are markedly different in Latin America than they are in other parts of the world. The most consistent epidemiologic data are available for candidemia, with a large prospective study in Brazil reporting an incidence that is 3-to 15-fold higher than that reported in studies from North America and Europe. Species distribution also differs: in Latin America, the most common Candida species (other than Candida albicans) causing bloodstream infections are Candida parapsilosis or Candida tropicalis, rather than Candida glabrata.
The incidence of invasive opportunistic mycoses has increased because of the expanding population of immunosuppressed patients, including solid-organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients, patients with cancer, patients with AIDS, premature neonates, elderly patients, and patients recovering from major surgery [1, 2] . Despite some effective treatment options, such mycoses are associated with high morbidity and mortality rates.
Opportunistic mycoses show distinct regional incidence patterns throughout the world and may exhibit different epidemiologic features, depending on the geographic region; this may be particularly true for mycoses (such as mold infections) that are acquired from the environment. Most epidemiologic data come from studies conducted in the northern hemisphere. Although some studies from Latin America have been Brito et al [6] and Colombo et al [7] ( 
OPPORTUNISTIC YEAST INFECTIONS
Invasive candidiasis. Candida remains the most important cause of opportunistic mycoses worldwide and a major cause of nosocomial bloodstream infection [3] . Patients at risk for invasive candidiasis include severely ill patients in intensive care units (ICUs), neutropenic patients with cancer, patients undergoing surgical procedures, and premature neonates [3] . Fungal surveillance programs have provided data regarding the incidence and species distribution of Candida bloodstream isolates across the world [3] . However, little has been reported from Latin American countries (Table 1 ). The Brazilian Network Candidemia Study reported an overall incidence of 2.49 cases per 1000 hospital admissions or 0.37 cases per 1000 patient-days [4] . Although differences in incidence rates are not directly comparable, because they are not risk adjusted, this high incidence is in sharp contrast to the lower incidence of candidemia reported in centers in the Northern Hemisphere, including the United States (0.28-0.96 cases per 1000 hospital admissions) [5] [6] [7] [8] , Canada (0.45 cases per 1000 hospital admissions) [9, Europe (0.20-0.38 cases per 1000 hospital admissions) [10] , France (0.17 cases per 1000 hospital admissions) [11] , Norway (0.17 cases per 1000 hospital admissions) [12] , Hungary (0.20-0.40 cases per 1000 hospital admissions) [13] , Switzerland (0.27 cases per 1000 hospital admissions) [14] , Italy (0.38 cases per 1000 hospital admissions) [15] , and Spain (0.76-0.81 cases per 1000 hospital admissions) [16, 17] . An even higher incidence (3.9 cases per 1000 hospital admissions) was reported in a single-center study from northeast Brazil [18] . An incidence of 0.38-0.83 cases per 1000 patient-days was reported in a single-center study in an ICU in Brazil [19] , and an incidence of 1.09 cases per 1000 ICU admissions was reported for a pediatric ICU in Argentina [20] . The reasons for the high incidence of candidemia in these series are not clear but may be related to a combination of factors, including differences in resources available for medical care and training programs, difficulties in the implementation of infection control programs in hospitals in developing countries, a limited number of health care workers available to assist patients in ICUs, and less aggressive practices of prophylaxis and empirical antifungal therapy. More data are needed to address this question.
Several studies characterizing the epidemiology, microbiology, risk factors, and/or patient outcomes associated with candidemia have been published (Table 1) [4, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Candida albicans is the leading agent, followed by Candida parapsilosis and Candida tropicalis. This is in sharp contrast to the higher incidence of Candida glabrata in the United States [5] . In the Brazilian Network Candidemia Study, C. albicans accounted for 40.9% of cases, followed by C. tropicalis (20.9%) and C. parapsilosis (20.5%); C. glabrata accounted for only 4.9% of cases [4] . This species distribution has been consistent across different studies from Brazil [32] [33] [34] , Argentina [35] [36] [37] , and Chile [30] . In a study of 2139 clinical isolates from Colombia, Ecuador, and Venezuela, the proportion of C. albicans isolates was higher (62%), but C. parapsilosis (11%) and C. tropicalis (8.5%) were again the most frequent non-albicans species, and C. glabrata accounted for only 3.5% of isolates [38] .
In the northern hemisphere, candidemia due to C. parapsilosis is clustered in neonates [39] , whereas in Latin America it is distributed through all ages, including (but not limited to) neonates [22, 23] . In a prospective observational study conducted in 4 tertiary care centers in Brazil from 2002 through 2003, C. parapsilosis accounted for 23% of cases. Patients with C. parapsilosis candidemia were more likely to have a tunneled central venous catheter, which supports the idea that an external source was the main mode of acquisition [23] .
Candidemia due to C. tropicalis has been associated with cancer, especially in patients with leukemia or neutropenia [40- Soil enriched with pigeon excreta, decaying wood, caged birds, vegetables, and dairy products [54] .
Cryptococcus gattii (serotypes B and C)
Prevalent only in tropical and subtropical regions. Serotype B was 4.5 times more prevalent than serotype C, and most type C isolates were from southern California.
Infections can be found in immunocompetent patients.
Tree detritus (eg, Eucalyptus species, Laurus species, and Terminalia catappa) [53] .
43]. In a study of 924 episodes of candidemia, 188 (20%) were caused by C. tropicalis; cancer was the most frequent underlying disease, and in adults and elderly patients, diabetes was the second most frequent underlying disease. Of note was the high proportion (12.3%) of candidemia cases due to C. tropicalis in neonates [22] . Rates 115% in European and North American general hospitals have only been reported in studies conducted in the 1980s and early 1990s; more recently, rates 115% have been reported in East and Southeast Asia, the Middle East, and Latin America [22] . In the Brazilian Network Candidemia Study, the incidence of candidemia due to C. glabrata was 0.12 cases per 1000 hospital admissions [4] . Recent data from 2 of the 11 hospitals involved in that study reported an incidence of 0.08 cases per 1000 admissions (unpublished data). A recent retrospective study from Brazil reported an increase in C. glabrata candidemia, from 8 (3.5%) of 228 cases from 1995 through 2003 to 28 (10.6%) of 263 cases from 2005 through 2007 [44] . The study also reported a relationship between fluconazole use and a greater incidence of C. glabrata candidemia [44] .
Candida guilliermondii and Candida rugosa are relatively uncommon agents of candidemia but appear to be increasingly reported [3] , including in Latin America [3, [45] [46] [47] [48] . A large pseudo-outbreak of C. guilliermondii fungemia was reported in a university hospital in Brazil [47] . Both C. guilliermondii and C. rugosa demonstrate decreased susceptibility to fluconazole and resistance to itraconazole [49, 50] . In a Brazilian study, C. rugosa exhibited increased resistance to both fluconazole and itraconazole over time [50] .
As indicated in Table 1 , antifungal resistance is infrequent in Latin America. In the largest study reporting the susceptibility profile of 1000 Candida bloodstream isolates, fluconazole resistance was restricted to 2 of 44 C. glabrata isolates, with no trend to an increase in the proportion of resistance in 2 periods (1995-1999 and 2000-2003) [49] .
Cryptococcosis. Cryptococcosis is caused by the Cryptococcus neoformans species complex. The geographic distribution of the disease, sources of C. neoformans infection, and clinical characteristics associated with the disease are summarized in Table 2 [51] [52] [53] [54] . C. neoformans is the agent of cryptococcosis that affects immunosuppressed patients, such as patients with AIDS [52] , SOT recipients, and patients with sarcoidosis or chronic lymphoproliferative diseases. By contrast, Cryptococcos gattii is the agent of the sporadic cryptococcosis that can affect immunocompetent individuals [55] . Although C. neoformans has a worldwide distribution [55] , C. gattii is found in tree detritus (Eucalyptus species, Laurus species, and Terminalia catappa) [53] and is geographically restricted to tropical and subtropical climates, including Australia, Cambodia, Central Africa, Brazil, Mexico, and Paraguay [51] . However, outbreaks of C. gattii infection have been recently reported in Vancouver Island and the surrounding area [55] .
The incidence of different Cryptococcus serotypes was evaluated in the IberoAmerican Cryptococcal Study Group: a total of 340 clinical, veterinary, and environmental isolates from Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela, Guatemala, and Spain were tested [56] . Of 177 clinical isolates obtained from patients with AIDS, 86% were serotype A, 7.4% were serotype AD hybrid, 3.4% were serotype D, and the remaining 2.8% were serotypes B and C [56] . In another study, 178 clinical isolates and 247 environmental isolates obtained from 5 regions of Colombia (1987 Colombia ( -2004 ) demonstrated a clinical isolate profile of serotypes A (91.1% of isolates), B (8.4%), and C (0.5%) and an environmental isolate profile of serotypes A (44.2%), B (42.6%), and C (13.2%); no serotype D or AD isolates were identified [53] . Finally, in another study of 100 [57] . All C. gattii isolates were from HIV-negative patients, and with the exception of the exclusive localization of C. neoformans serotype AD among Chilean isolates, no particular serotype distribution was related to any geographic area [57] . A report on HIV-related opportunistic diseases published by the Joint United Nations Programme on HIV/AIDS in 1998 reported the following prevalence rates for cryptococcosis: Zaire, 19% of cases of HIV-related opportunistic disease; Mexico, 7%-11%; United States, 7%; Brazil, 5%; Ivory Coast, 5%; and Thailand, 2% [58] . In a Colombian national survey that included 931 patients from 76 centers from 1997 through 2005, 78.1% had HIV infection; the mean annual incidence of cryptococcosis was found to be 2.4 cases per 1 million inhabitants in the general population and 3 cases per 1000 patients with AIDS [59] .
Of 1215,000 patients with AIDS registered in Brazil in 1980-2002, 6% had cryptococcosis at the time of diagnosis [60] . Estimates of the overall mortality due to cryptococcosis in Brazil range from 45% to 65%, and 1 study reported a mortality rate of 79% among patients with AIDS [61] .
A Mexican autopsy study of 177 patients with AIDS identified central nervous system involvement by cryptococcosis in 10% of cases before the era of highly active antiretroviral therapy (HAART) [62] . In another Mexican study, among 211 Cryptococcus isolates, 183 (86.7% were C. neoformans var. neoformans, and 10.4% were var. gattii. AIDS was the most frequent underlying disease [63] .
The adoption of HAART has been associated with a decrease in the incidence of opportunistic infections, including cryptococcosis. A single-center study conducted in Brazil reported a decrease in the incidence of central nervous system cryptococcosis among patients with AIDS from 7.7% in 1995 to 3.1% in 2001 [61] . In a case-control study conducted among HIVpositive Chilean patients, the prevalence of cryptococcosis was reduced by 66% with the use of HAART [64] . In another Chilean study involving 1057 HIV-positive patients, the prevalence of cryptococcal meningitis was reported to be reduced from 3.4% to 0% with the introduction of HAART in treatmentnaive patients [65] .
OPPORTUNISTIC MOLD INFECTIONS
Invasive aspergillosis (IA). The incidence of IA is increasing, with estimates ranging from 2.6% to 6.9% [66] [67] [68] [69] , and it is most commonly caused by Aspergillus fumigatus [66, 69] . The main risk factors are prolonged and profound neutropenia and severe T cell-mediated immunodeficiency due to various factors, including high-dose corticosteroids, graft-versus-host disease, cytomegalovirus reactivation in HSCT recipients, and the use of monoclonal antibodies and nucleoside analogs [70] [71] [72] [73] [74] . A wide range of associated mortality rates (42%-77%) have been reported [66, 69, 70] .
Data on IA incidence in Latin America are scarce. Preliminary data from a prospective survey involving HSCT recipients and patients with acute myeloid leukemia or myelodysplastic syndromes undergoing induction and consolidation chemotherapy at 8 hematology centers in Brazil (most of whom received fluconazole prophylaxis) reported that IA was the leading invasive mycosis (30 [6.5%] of 460 patients) and that its prevalence was 6 times greater among patients with acute myeloid leukemia [75] . An autopsy study reported 5 deaths due to IA among 925 pediatric patients in Mexico from 1976 through 1990 [76] . In another study, pulmonary IA was identified in 7 (2.2%) of 307 patients with AIDS in a Cuban autopsy study (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) [77] .
Of 64 HSCT recipients who received fluconazole prophylaxis at 2 hospitals in São Paulo, Brazil, during the period 1993-1998, 5 developed invasive mold infections; 2 (5%) had invasive mold infections that were caused by Aspergillus [78] .
Invasive fusariosis. Fusarium is a plant pathogen and a soil saprophyte that can cause a broad spectrum of infections in humans, including disseminated infection (invasive fusariosis) [79] . Risk factors for invasive fusariosis are similar to those for IA (prolonged and profound neutropenia and severe T cellmediated immunodeficiency). Skin breakdowns, particularly at onychomycosis sites, may serve as portals of entry [79] [80] [81] [82] . The mortality rate associated with invasive fusariosis ranges from 50% to ∼90% [66, [83] [84] [85] [86] .
In a retrospective analysis of 84 patients (79 with hematologic malignant neoplasms and 5 with aplastic anemia) with invasive fusariosis who were treated in Brazil (11 centers) and the United States (1 center) [86] , fever was the most frequent clinical manifestation (92% of cases), followed by skin lesions (77%). Fusariosis was disseminated in 79% of patients and localized in 10.7%; fungemia without apparent organ involvement was present in 10.7% [86] . The most frequently reported pathogen was Fusarium solani (in 18 of 30 patients); only 21% of patients were alive 90 days after diagnosis [86] . A retrospective review of 61 HSCT recipients (54 with allogeneic stem cell transplants and 7 with autologous stem cell transplants) who developed invasive fusariosis (2 centers in the United States and 7 in Brazil) during the period 1985-2001 found that disseminated infection, again with metastatic skin lesions, was the most frequent clinical presentation (75% of cases), followed by fungemia alone (11%) and sinusitis and pneumonia (6.6% each) [85] . Although the overall incidence of fusariosis (5.97 cases per 1000 transplant recipients) varied among the different institutions (range, 5.00-11.33 cases per 1000 transplant recipi-ents), it did not vary among the countries (6.18 cases per 1000 transplant recipients in Brazil vs 5.89 cases per 1000 transplant recipients in the United States) [85] . Compared with US patients, Brazilian patients were younger, were more likely to have chronic myelogenous leukemia or aplastic anemia, were more likely to have received an human leukocyte antigen-compatible related donor transplant, and were more likely to be neutropenic when fusariosis was diagnosed [85] . The median duration of survival after diagnosis was 13 days; only 13% of patients were alive 90 days after diagnosis.
Other molds. Reports of zygomycosis from individual Latin American countries have been limited to case reports only [87] [88] [89] . The incidence of phaeohyphomycosis, an infection caused by dematiaceous fungi, appears to be increasing [90] [91] [92] [93] . A 2002 review of 72 published cases of phaeohyphomycosis noted that 75% of cases (and 100% of those that involved Scedosporium prolificans) were reported from 1992 through 2001 [92] . Most patients were from Europe (28 patients) and North America (23), whereas there were fewer reports from Australia (9), the Middle East (4), South America (4), and Asia (3) [92] . The greatest number of cases were caused by S. prolificans (Scedosporium inflatum; 41.7%); other important causative species were Bipolaris spicifera (8.3%) and Wangiella dermatitidis (Exophiala dermatitidis; 6.9%) [92] . Major risk factors for developing phaeohyphomycosis are immunosuppression (especially neutropenia), malignant neoplasm (especially leukemia), SOT, heart valve replacement, diabetes, and asthma [92, 94] . The overall mortality rate in the 2002 case series was 79% (84% among patients with immunodeficiency) [92] .
Reports of phaeohyphomycosis from individual Latin American countries have been limited, and there have been no published cases due to S. prolificans. From 1996 through 1997, 23 cases of fungemia due to nosocomial Exophiala jeanselmei (caused by contaminated hospital water) were diagnosed in Rio de Janeiro, Brazil [95] . Reports of other phaeohyphomycosis cases are summarized in Table 3 [96] [97] [98] [99] .
CONCLUSION
A number of clinically significant opportunistic infections occur in Latin America, each associated with specific risk factors. The incidence of some opportunistic infections is markedly different in Latin America than in other parts of the world. Still other opportunistic infections have not been studied enough to draw comparative conclusions. The profile of Candida species most closely associated with candidemia and other types of invasive candidiasis is different in Latin America than in North America and Europe. Consistent with trends in many other parts of the world, the incidence of invasive infections caused by some opportunistic mycoses in Latin America appears to be increasing.
